Where does smoldering collide?

In fire science, smouldering is a slow, low-temperature, flameless form of combustion sustained by the heat released when oxygen attacks the surface of a porous or finely divided solid fuel such as peat, dust, upholstery foam, or a cigarette-ignited mattress. Palmer's 1957 Smouldering combustion in dusts and fibrous materials characterised how the reaction creeps through such fuels, and Ohlemiller's 1985 Modeling of smoldering combustion propagation set out the oxygen-supply and heat-transfer balance that governs whether the front advances, dies, or transitions to open flaming. The referent is a self-propagating oxidation front inside a solid, dangerous because it ignites easily, persists hidden for hours, and can flare into flaming fire, and it has nothing in common with an asymptomatic blood cancer beyond the shared image of something burning quietly.[1][2]

Unit

The speed and temperature of a self-sustaining smoulder front through a solid fuel

Recovery means

Not applicable

Measured by

Characterised by smoulder propagation velocity, peak front temperature, oxygen consumption, and the critical conditions for extinction or transition to flaming

In hematology, smoldering (multiple) myeloma names an asymptomatic intermediate stage between benign monoclonal gammopathy and active multiple myeloma: the patient has a substantial plasma-cell clone and paraprotein but none of the organ damage (bone lesions, anemia, kidney failure, hypercalcemia) that would mandate treatment. Kyle and Greipp's 1980 Smoldering multiple myeloma defined the category from patients who met marrow and protein criteria yet stayed stable and untreated for years. The referent is a clinically defined disease phase marked by watchful waiting and a measurable risk of progression, borrowing the word only for the meaning of a process quietly burning below the threshold of overt fire.[3]

Unit

Plasma-cell burden and paraprotein level without end-organ damage

Recovery means

Not applicable

Measured by

Established by bone-marrow plasma-cell percentage and serum/urine monoclonal protein in the absence of myeloma-defining organ damage, with progression tracked over time